First human use for Orbus' bio-engineered stent:
This article was originally published in Clinica
The first human implant of Orbus Medical Technologies' bio-engineered coronary stent for preventing restenosis took place last week. The coronary R stent incorporates a bio-engineered surface, called Genous, which uses antibodies to capture the patient's own circulating endothelial progenitor cells (EPCs) and recruit them to the stent's surface (see Clinica No 1028, p 19). After rapidly covering the surface, the EPCs differentiate into mature endothelial cells, and within hours provide an effective barrier against the processes that can initiate restenosis, says the Fort Lauderdale, Florida firm. The technology may also have use in peripheral stents, artificial grafts and heart valves.